ICER identifies most significant 2019 US drug price hikes — even after rebates — that were not supported by new clinical evidence

ICER

12 January 2021 - Out of 10 identified drugs that had substantial 2019 price increases on top of already high current spending, seven were not supported by new clinical evidence; the net price increases on these seven drugs alone cost Americans an additional $1.2 billion in annual drug spend.

The Institute for Clinical and Economic Review (ICER) today published its latest report on unsupported price increases of prescription drugs in the United States. 

Among the top drugs with price increases in 2019 that had substantial effects on US spending, ICER determined that seven of 10 lacked adequate new evidence to demonstrate a substantial clinical benefit that was not yet previously known. 

Read ICER Announcement

Michael Wonder

Posted by:

Michael Wonder